TY - JOUR T1 - Risk of venous thromboembolism in oral contraceptive users varies according to progestin type JF - Evidence Based Nursing JO - Evid Based Nurs SP - 82 LP - 83 DO - 10.1136/ebnurs-2011-100480 VL - 15 IS - 3 AU - Susan S Jick Y1 - 2012/07/01 UR - http://ebn.bmj.com/content/15/3/82.abstract N2 - Commentary on: Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 2011;343:d6423.OpenUrlAbstract/FREE Full Text ■ Combined oral contraceptives (OCs) increase the risk of venous thromboembolism (VTE).■ The risk of VTE in users of OCs containing desogestrel, gestodene, cyproterone and drospirenone is around twice that of levonorgestrel OCs users.■ Differences in VTE risk should be taken into consideration when prescribing OCs. Oral contraceptives first introduced in the 1960s contained high doses of estrogen and progestin. These were associated with increased risk for cardiovascular disease (CVD), including VTE, and high estrogen dose was thought to be responsible.1 In subsequent years, OCs containing lower estrogen doses and different progestins … ER -